Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026
Go back to Agenus Reports Landmark BOT+BAL Data Showing 33% Three-Year Overall Survival in Refractory MSS Metastatic Colorectal Cancer Without Active Liver Metastases at ESMO GI 2026| AGENUS (NASDAQ: AGEN) | Delayed: 7.22 --0 (-0%) | |||||
|---|---|---|---|---|---|---|
| Previous Close | $7.22 | 52 Week High | $7.49 | |||
| Open | $7.22 | 52 Week Low | $2.61 | |||
| Day High | $7.22 | P/E | N/A | |||
| Day Low | $7.22 | EPS | $-1.10 | |||
| Volume | 30,943 | |||||
